Protagonist Therapeutics
PTGX
66 hedge funds and large institutions have $93.2M invested in Protagonist Therapeutics in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 9 closing their positions.
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
8% more funds holding
Funds holding: 61 → 66 (+5)
9.07% less ownership
Funds ownership: 66.36% → 57.29% (-9.1%)
43% less capital invested
Capital invested by funds: $165M → $93.2M (-$71.6M)
52% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 31
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management III
New York
|
+$3.36M |
| 2 |
VMI
VHCP Management II
New York
|
+$1.98M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.35M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.03M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$970K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.76M |
| 2 |
Jennison Associates
New York
|
-$3.6M |
| 3 |
Millennium Management
New York
|
-$2.73M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.6M |
| 5 |
Renaissance Technologies
New York
|
-$1.57M |
PTGX Hedge Fund Activity: Q4 2018 in Review
66 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2018, worth a combined $93.2M — down 43% from $165M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PTGX positions and 9 closed out — a net gain of 8 holders — while 15 added to existing stakes and 31 trimmed.
The largest buyer was VHCP Management III, opening a new position worth an estimated $3.36M. The largest seller was BVF Inc, cutting an estimated $7.76M.
- 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2018, up from 61 in Q3 2018.
- Funds reported $93.2M of Protagonist Therapeutics stock for Q4 2018, down 43% quarter-over-quarter.
- 17 funds opened new Protagonist Therapeutics positions in Q4 2018 and 9 closed out, a net change of +8 holders.
- The largest Protagonist Therapeutics buyer in Q4 2018 was VHCP Management III, an estimated $3.36M added.
- The largest Protagonist Therapeutics seller in Q4 2018 was BVF Inc, an estimated $7.76M sold.
Based on aggregated 13F filings for Q4 2018.